{"id":"W4200000996","doi":"10.1161/jaha.121.024033","title":"Cardiovascular Safety Assessment in Cancer Drug Development","year":2021,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Ironwood Pharmaceuticals, Incorporated; National Institute of Allergy and Infectious Diseases; HLS Therapeutics; Duke Clinical Research Institute; Eisai; Belvoir Media Group; MyoKardia; Novo Nordisk; Medicines Company; AstraZeneca; Amarin Corporation; St. Jude Medical; Regeneron Pharmaceuticals; Boston Scientific Corporation; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; CSL Behring; Idorsia Pharmaceuticals; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer","keywords":"Cardiotoxicity; Drug development; Clinical trial; Drug; Cancer; Hematology; Risk assessment; Cardiovascular event; Endpoint Determination; Cardiac toxicity","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1107644,0.0008336818,0.001899699,0.002733174,0.00102644,0.004692631,0.001892945,0.00303437,0.002038961],"category_scores_gemma":[0.1246432,0.0003266933,0.001413679,0.001728601,0.003044516,0.002465286,0.002546247,0.004069252,0.000736783],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002049022,"about_ca_system_score_gemma":0.006754075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009867779,"about_ca_topic_score_gemma":0.001041148,"domain_scores_codex":[0.8981579,0.07212851,0.01037272,0.002340129,0.01624734,0.0007533907],"domain_scores_gemma":[0.8173639,0.1147749,0.02619386,0.006757965,0.03253465,0.002374736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.001576038,0.0004501184,0.04232868,0.008593078,0.0008482377,0.001003293,0.001407489,0.009323187,0.007957832,0.1010686,0.03836017,0.7870831],"study_design_scores_gemma":[0.000465515,0.01090864,0.04711848,0.01426633,0.001861465,0.005771423,0.0014062,0.0185247,0.03053949,0.1164877,0.7522784,0.0003717063],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.05278764,0.493856,0.2742775,0.08152454,0.006247501,0.003146602,0.002236367,0.0007989768,0.08512487],"genre_scores_gemma":[0.5990161,0.1723125,0.1745134,0.03400769,0.00886206,0.002327188,0.001743575,0.0002036886,0.00701376],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1107644,"threshold_uncertainty_score":0.585785,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01289528230843646,"score_gpt":0.2981959608689757,"score_spread":0.2853006785605392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}